CA3060394A1 - Pyrimidine derivatives as pge2 receptor modulators - Google Patents

Pyrimidine derivatives as pge2 receptor modulators Download PDF

Info

Publication number
CA3060394A1
CA3060394A1 CA3060394A CA3060394A CA3060394A1 CA 3060394 A1 CA3060394 A1 CA 3060394A1 CA 3060394 A CA3060394 A CA 3060394A CA 3060394 A CA3060394 A CA 3060394A CA 3060394 A1 CA3060394 A1 CA 3060394A1
Authority
CA
Canada
Prior art keywords
pyrimidin
ethylamino
benzo
ethoxy
methoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3060394A
Other languages
English (en)
French (fr)
Inventor
Christoph Boss
Olivier Corminboeuf
Heinz Fretz
Isabelle Lyothier
Davide Pozzi
Sylvia Richard-Bildstein
Herve Siendt
Thierry Sifferlen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Idorsia Pharmaceuticals Ltd
Original Assignee
Idorsia Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idorsia Pharmaceuticals Ltd filed Critical Idorsia Pharmaceuticals Ltd
Publication of CA3060394A1 publication Critical patent/CA3060394A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Electrochromic Elements, Electrophoresis, Or Variable Reflection Or Absorption Elements (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA3060394A 2017-05-18 2018-05-17 Pyrimidine derivatives as pge2 receptor modulators Pending CA3060394A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP2017061989 2017-05-18
EPPCT/EP2017/061989 2017-05-18
PCT/EP2018/062844 WO2018210988A1 (en) 2017-05-18 2018-05-17 Pyrimidine derivatives as pge2 receptor modulators

Publications (1)

Publication Number Publication Date
CA3060394A1 true CA3060394A1 (en) 2018-11-22

Family

ID=62196584

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3060394A Pending CA3060394A1 (en) 2017-05-18 2018-05-17 Pyrimidine derivatives as pge2 receptor modulators

Country Status (32)

Country Link
US (1) US11839613B2 (cg-RX-API-DMAC7.html)
EP (1) EP3625228B1 (cg-RX-API-DMAC7.html)
JP (1) JP7159215B2 (cg-RX-API-DMAC7.html)
KR (1) KR102626982B1 (cg-RX-API-DMAC7.html)
CN (1) CN110612299A (cg-RX-API-DMAC7.html)
AR (1) AR111808A1 (cg-RX-API-DMAC7.html)
AU (1) AU2018268311B2 (cg-RX-API-DMAC7.html)
BR (1) BR112019024105A2 (cg-RX-API-DMAC7.html)
CA (1) CA3060394A1 (cg-RX-API-DMAC7.html)
CL (1) CL2019003274A1 (cg-RX-API-DMAC7.html)
CO (1) CO2019010505A2 (cg-RX-API-DMAC7.html)
CR (1) CR20190560A (cg-RX-API-DMAC7.html)
CY (1) CY1124799T1 (cg-RX-API-DMAC7.html)
DK (1) DK3625228T3 (cg-RX-API-DMAC7.html)
EA (1) EA201992677A1 (cg-RX-API-DMAC7.html)
ES (1) ES2887041T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20211380T1 (cg-RX-API-DMAC7.html)
HU (1) HUE056382T2 (cg-RX-API-DMAC7.html)
IL (1) IL270620B2 (cg-RX-API-DMAC7.html)
LT (1) LT3625228T (cg-RX-API-DMAC7.html)
MA (1) MA49128A (cg-RX-API-DMAC7.html)
MX (1) MX388257B (cg-RX-API-DMAC7.html)
PE (1) PE20191811A1 (cg-RX-API-DMAC7.html)
PH (1) PH12019502564A1 (cg-RX-API-DMAC7.html)
PL (1) PL3625228T3 (cg-RX-API-DMAC7.html)
PT (1) PT3625228T (cg-RX-API-DMAC7.html)
RS (1) RS62398B1 (cg-RX-API-DMAC7.html)
SG (1) SG11201908097YA (cg-RX-API-DMAC7.html)
SI (1) SI3625228T1 (cg-RX-API-DMAC7.html)
TW (1) TW201900178A (cg-RX-API-DMAC7.html)
UA (1) UA125124C2 (cg-RX-API-DMAC7.html)
WO (1) WO2018210988A1 (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20180323A (es) 2015-11-20 2018-08-06 Idorsia Pharmaceuticals Ltd Derivados de indol n-sustituídos como moduladores de los receptores de pge2
EP3625227B1 (en) 2017-05-18 2022-09-14 Idorsia Pharmaceuticals Ltd Benzofurane and benzothiophene derivatives as pge2 receptor modulators
WO2018210992A1 (en) 2017-05-18 2018-11-22 Idorsia Pharmaceuticals Ltd Pyrimidine derivatives
SI3625222T1 (sl) 2017-05-18 2021-11-30 Idorsia Pharmaceuticals Ltd Derivati fenila kot modulatorji receptorja pge2
WO2021060281A1 (ja) * 2019-09-24 2021-04-01 Ａｇｃ株式会社 プロスタグランジンｅ２レセプターｅｐ２／ｅｐ４デュアルアンタゴニスト
AU2021328671A1 (en) * 2020-08-18 2023-02-16 Cybin Irl Limited Phenethylamine derivatives, compositions, and methods of use
EP4245301A4 (en) 2020-11-13 2024-08-21 ONO Pharmaceutical Co., Ltd. TREATMENT OF CANCER BY COMBINED USE OF AN EP4 ANTAGONIST AND AN IMMUNE CHECKPOINT INHIBITOR
EP4359399A4 (en) 2021-06-24 2025-04-23 Reservoir Neuroscience, Inc. EP2 antagonist compounds
CN113248354B (zh) * 2021-07-07 2022-04-22 山东国邦药业有限公司 一种氟氯苯乙酮的合成方法
US12492178B2 (en) 2021-09-01 2025-12-09 Empathbio, Inc. Stable polymorph of R-MDMA HCl
WO2023129958A2 (en) 2021-12-28 2023-07-06 ATAI Life Sciences AG Nitric oxide releasing prodrugs of mda and mdma
CN114539193B (zh) * 2022-01-20 2024-08-06 安徽普利药业有限公司 一种盐酸胺碘酮中间体的制备方法
CN116041245B (zh) * 2022-12-30 2025-03-07 上海毕得医药科技股份有限公司 一种4-(二氟甲氧基)-1h-吲哚-2-羧酸的制备方法
WO2024149728A1 (en) 2023-01-10 2024-07-18 Astrazeneca Ab Substituted (hetero)anilines and their use
WO2025149498A1 (en) 2024-01-09 2025-07-17 Astrazeneca Ab Benzylpiperidine derivatives as trp4 antagonists for the treatment of inflammatory diseases
WO2025229177A1 (en) 2024-05-02 2025-11-06 Idorsia Pharmaceuticals Ltd Crystalline forms of an n-substituted indole derivative

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5948786A (en) 1996-04-12 1999-09-07 Sumitomo Pharmaceuticals Company, Limited Piperidinylpyrimidine derivatives
DE60038902D1 (de) 2000-03-24 2008-06-26 Asterand Uk Ltd Verwendung von prostanoid-ep4-rezeptor-antagonisten zur behandlung von kopfschmerzen und nachweisverfahren für solche antagonisten
HN2001000224A (es) 2000-10-19 2002-06-13 Pfizer Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti - inflamatorios y analgesicos.
GB0031302D0 (en) 2000-12-21 2001-01-31 Glaxo Group Ltd Napthalene derivatives
GB0031295D0 (en) 2000-12-21 2001-01-31 Glaxo Group Ltd Naphthalene derivatives
GB0103269D0 (en) 2001-02-09 2001-03-28 Glaxo Group Ltd Napthalene derivatives
AU2003216579A1 (en) 2002-04-12 2003-10-27 Pfizer Inc. Imidazole compounds as anti-inflammatory and analgesic agents
MXPA04009960A (es) 2002-04-12 2004-12-13 Pfizer Compuestos de pirazol como agentes anti-inflamatorios y analgesicos.
AU2003233297A1 (en) 2002-05-23 2003-12-12 Theratechnologies Inc Antagonistic peptides of prostaglandin e2 receptor subtype ep4
ATE396182T1 (de) 2003-01-29 2008-06-15 Asterand Uk Ltd Hemmstoffe des ep4-rezeptors
CN1871240B (zh) 2003-08-26 2012-11-07 帝人制药株式会社 吡咯并嘧啶酮衍生物
KR100747401B1 (ko) 2003-09-03 2007-08-08 화이자 인코포레이티드 프로스타글란딘 ｅ2 길항제로서의 페닐 또는 피리딜 아미드 화합물
EP1678147B1 (en) 2003-09-15 2012-08-08 Lead Discovery Center GmbH Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases
GB0324269D0 (en) 2003-10-16 2003-11-19 Pharmagene Lab Ltd EP4 receptor antagonists
AP2006003769A0 (en) 2004-05-04 2006-10-31 Pfizer Ortho substituted aryl or heteroaryl amide compounds
EP1756042B8 (en) 2004-05-04 2014-06-04 RaQualia Pharma Inc Substituted methyl aryl or heteroaryl amide compounds
GT200500284A (es) 2004-10-15 2006-03-27 Aventis Pharma Inc Pirimidinas como antagonistas del receptor de prostaglandina d2
WO2006122403A1 (en) 2005-05-19 2006-11-23 Merck Frosst Canada Ltd. Quinoline derivatives as ep4 antagonists
WO2006128129A2 (en) 2005-05-26 2006-11-30 Synta Pharmaceuticals Corp. Method for treating cancer
DOP2007000068A (es) 2006-04-12 2007-10-31 Sanofi Aventis Us Llc Compuestos de amino-pirimidina 2,6-sustituidos-4-monosustituidos como antagonistas del receptor de prostaglandina d2
US7968578B2 (en) 2006-04-24 2011-06-28 Merck Frosst Canada Ltd. Indole amide derivatives as EP4 receptor antagonists
EP2035376B1 (en) 2006-06-12 2014-08-27 Merck Canada Inc. Indoline amide derivatives as ep4 receptor ligands
US20080280891A1 (en) 2006-06-27 2008-11-13 Locus Pharmaceuticals, Inc. Anti-cancer agents and uses thereof
WO2008008059A1 (en) 2006-07-12 2008-01-17 Locus Pharmaceuticals, Inc. Anti-cancer agents ans uses thereof
AR061974A1 (es) 2006-07-14 2008-08-10 Novartis Ag Derivados de pirimidina como inhibidores de alk, composiciones farmaceuticas y procesos de obtencion
EP2054401B1 (en) 2006-08-11 2013-05-01 Merck Canada Inc. Thiophenecarboxamide derivatives as ep4 receptor ligands
WO2008039882A1 (en) 2006-09-30 2008-04-03 Sanofi-Aventis U.S. Llc A combination of niacin and a prostaglandin d2 receptor antagonist
CN101622230B (zh) 2007-02-26 2012-08-22 默克弗罗斯特加拿大有限公司 作为ep4受体拮抗剂的吲哚和二氢吲哚环丙基酰胺衍生物
US8030489B2 (en) 2007-03-26 2011-10-04 Astellas Pharma Inc. Ornithine derivative
CN101636385B (zh) 2007-03-26 2012-09-05 默克弗罗斯特加拿大有限公司 作为ep4受体拮抗剂的萘和喹啉磺酰脲衍生物
EP2014657A1 (de) * 2007-06-21 2009-01-14 Bayer Schering Pharma Aktiengesellschaft Diaminopyrimidine als Modulatoren des EP2-Rezeptors
WO2009005076A1 (ja) 2007-07-03 2009-01-08 Astellas Pharma Inc. アミド化合物
SI2212297T1 (sl) 2007-10-12 2011-09-30 Ingenium Pharmaceuticals Gmbh Inhibitorji protein kinaz
CA2714743C (en) 2008-02-19 2017-01-17 Janssen Pharmaceutica N.V. Aryl-hydroxyethylamino-pyrimidines and triazines as modulators of fatty acid amide hydrolase
JP5375824B2 (ja) 2008-05-14 2013-12-25 アステラス製薬株式会社 アミド化合物
US20130225528A1 (en) 2008-05-21 2013-08-29 Ariad Pharmaceuticals, Inc. Phosphorus Derivatives as Kinase Inhibitors
US8404736B2 (en) 2008-08-14 2013-03-26 Beta Pharma Canada Inc. Heterocyclic amide derivatives as EP4 receptor antagonists
CN102164942B (zh) 2008-09-19 2017-02-15 生物科技研究有限公司 三萜系化合物及其使用的方法
EP2346866B1 (en) 2008-09-25 2013-11-27 Merck Canada Inc. Beta-carboline sulphonylurea derivatives as ep4 receptor antagonists
US8906914B2 (en) * 2009-08-18 2014-12-09 Janssen Pharmaceutica Nv Ethylene diamine modulators of fatty acid hydrolase
US20110124667A1 (en) 2009-11-23 2011-05-26 Philip Manton Brown Methods for the treatment of irritable bowel syndrome
MX2012013274A (es) 2010-05-21 2013-05-28 Chemilia Ab Novedosos derivados de la pirimidina.
ME02575B (me) 2010-09-21 2017-06-20 Eisai R&D Man Co Ltd Farmaceutska kompozicija
CN106046158A (zh) 2010-09-29 2016-10-26 株式会社Nb健康研究所 针对人前列腺素e2 受体ep4 的抗体
WO2012066065A1 (en) 2010-11-17 2012-05-24 Novartis Ag Phenyl-heteroaryl amine compounds and their uses
EA201390717A1 (ru) 2010-11-17 2013-10-30 Новартис Аг 3-(аминоарил)пиридиновые соединения
EP2649061B1 (en) 2010-12-10 2015-05-13 Rottapharm Biotech S.r.l. Pyridine amide derivatives as ep4 receptor antagonists
WO2012103071A2 (en) 2011-01-25 2012-08-02 Eisai R&D Management Co., Ltd. Compounds and compositions
JP5886411B2 (ja) 2011-03-24 2016-03-16 ノビガ・リサーチ・エービーＮｏｖｉｇａ Ｒｅｓｅａｒｃｈ ＡＢ 新規のピリミジン誘導体
EP2702043A1 (en) 2011-04-29 2014-03-05 Exelixis, Inc. Inhibitors of inducible form of 6-phosphofructose-2-kinase
CA2839956A1 (en) 2011-06-20 2012-12-27 Emory University Prostaglandin receptor ep2 antagonists, derivatives, compositions, and uses related thereto
RU2565596C2 (ru) 2011-07-04 2015-10-20 Роттафарм Биотек С.Р.Л. Производные циклических аминов в качестве антагонистов рецептора ер4
EP2554662A1 (en) 2011-08-05 2013-02-06 M Maria Pia Cosma Methods of treatment of retinal degeneration diseases
US20150004175A1 (en) 2011-12-13 2015-01-01 Yale University Compositions and Methods for Reducing CTL Exhaustion
IN2014KN02601A (cg-RX-API-DMAC7.html) * 2012-04-24 2015-05-08 Vertex Pharma
AR091429A1 (es) 2012-06-29 2015-02-04 Lilly Co Eli Compuestos de fenoxietil piperidina
TWI572597B (zh) 2012-06-29 2017-03-01 美國禮來大藥廠 二甲基－苯甲酸化合物
EP2711364A1 (en) 2012-09-21 2014-03-26 Chemilia AB 4-(Indolyl or benzimidazolyl)amino-2-(2-(indol-3-yl)ethyl)aminopyrimidines useful for the treatment of cancer
PE20151412A1 (es) 2012-11-27 2015-10-10 Thomas Helledays Stiftelse For Medicinsk Forskning Derivados de pirimidin-2,4-diamina para el tratamiento de cancer
UA115576C2 (uk) 2012-12-06 2017-11-27 Байєр Фарма Акцієнгезелльшафт Похідні бензимідазолу як антагоністи ер4
EP2765128A1 (en) 2013-02-07 2014-08-13 Almirall, S.A. Substituted benzamides with activity towards EP4 receptors
TW201443004A (zh) 2013-02-15 2014-11-16 Lilly Co Eli 苯氧基乙氧基化合物
TWI636046B (zh) 2013-05-17 2018-09-21 美國禮來大藥廠 苯氧基乙基二氫－１ｈ－異喹啉化合物
CN105263924B (zh) 2013-05-30 2018-10-19 爱杜西亚制药有限公司 Cxcr7受体调节剂
HUE039015T2 (hu) 2013-06-12 2018-12-28 Kaken Pharma Co Ltd 4-Alkinil-imidazol-származék és ezt hatóanyagként tartalmazó gyógyszerkészítmény
CN105705489B (zh) 2013-09-04 2019-04-26 百时美施贵宝公司 用作免疫调节剂的化合物
RS57508B1 (sr) 2013-09-06 2018-10-31 Aurigene Discovery Tech Ltd 1,2,4-derivati oksadiazola kao imunomodulatori
WO2015044900A1 (en) 2013-09-27 2015-04-02 Aurigene Discovery Technologies Limited Therapeutic immunomodulating compounds
MX361488B (es) 2013-10-17 2018-12-07 Vertex Pharma Cocristales de (s)-n-metil-8-(1-((2'-metil-[4,5'-bipirimidin]-6-il ) amino)propan-2-il)quinolina-4-carboxamida y sus derivados deuterados como inhibidores de proteínas cinasa dependientes de adn (adn-pk).
BR112016008423B1 (pt) 2013-10-17 2022-02-22 Vertex Pharmaceuticals Incorporated Composto, composição farmacêutica compreendendo o mesmo e seu uso
ES2727329T3 (es) 2013-12-17 2019-10-15 Lilly Co Eli Compuestos de ácido dimetilbenzoico
LT3083562T (lt) 2013-12-17 2018-01-10 Eli Lilly & Company Fenoksietilo cikliniai amino dariniai ir jų aktyvumas kaip ep4 receptoriaus moduliatorių
TW201607943A (zh) 2013-12-19 2016-03-01 拜耳製藥公司 作為ｅｐ４配體之新穎苯并咪唑衍生物
TW201623277A (zh) 2014-03-26 2016-07-01 安斯泰來製藥股份有限公司 醯胺化合物
EP3137074B1 (en) 2014-04-29 2020-08-05 Emory University Prostaglandin receptor ep2 antagonists, derivatives, compositions, and uses related thereto
CA2949961C (en) 2014-05-23 2023-09-19 Eisai R&D Management Co., Ltd. Combination therapies for the treatment of cancer
WO2015187089A1 (en) 2014-06-04 2015-12-10 Thomas Helledays Stiftelse För Medicinsk Forskning Mth1 inhibitors for treatment of inflammatory and autoimmune conditions
SG11201610517PA (en) 2014-06-19 2017-01-27 Ariad Pharma Inc Heteroaryl compounds for kinase inhibition
WO2016021742A1 (en) 2014-08-07 2016-02-11 Takeda Pharmaceutical Company Limited Heterocyclic compounds as ep4 receptor antagonists
TWI783617B (zh) 2015-01-09 2022-11-11 日商小野藥品工業股份有限公司 三環性螺化合物之用途
DK3325490T3 (da) 2015-07-23 2020-02-03 Takeda Pharmaceuticals Co 1-substituerede 1,2,3,4-tetrahydro-1,7-naphthyridin-8-aminderivater og deres anvendelse som ep4-receptorantagonister
MX390051B (es) 2015-10-16 2025-03-20 Eisai R&D Man Co Ltd Antagonistas de ep4.
CR20180323A (es) 2015-11-20 2018-08-06 Idorsia Pharmaceuticals Ltd Derivados de indol n-sustituídos como moduladores de los receptores de pge2
CN109863143B (zh) 2016-07-13 2021-10-15 威泰克斯制药公司 提高基因组编辑效率的方法、组合物和试剂盒
SI3625222T1 (sl) 2017-05-18 2021-11-30 Idorsia Pharmaceuticals Ltd Derivati fenila kot modulatorji receptorja pge2
EP3625227B1 (en) 2017-05-18 2022-09-14 Idorsia Pharmaceuticals Ltd Benzofurane and benzothiophene derivatives as pge2 receptor modulators
TWI768043B (zh) 2017-05-18 2022-06-21 瑞士商愛杜西亞製藥有限公司 N-取代吲哚衍生物
WO2018210992A1 (en) 2017-05-18 2018-11-22 Idorsia Pharmaceuticals Ltd Pyrimidine derivatives

Also Published As

Publication number Publication date
AU2018268311B2 (en) 2022-02-10
US11839613B2 (en) 2023-12-12
EP3625228B1 (en) 2021-07-07
WO2018210988A1 (en) 2018-11-22
SG11201908097YA (en) 2019-10-30
AU2018268311A1 (en) 2020-01-16
CY1124799T1 (el) 2022-11-25
ES2887041T3 (es) 2021-12-21
PH12019502564A1 (en) 2020-09-14
HUE056382T2 (hu) 2022-02-28
JP2020520358A (ja) 2020-07-09
IL270620B2 (en) 2023-04-01
HRP20211380T1 (hr) 2021-11-26
DK3625228T3 (da) 2021-10-11
RS62398B1 (sr) 2021-10-29
CN110612299A (zh) 2019-12-24
MA49128A (fr) 2021-03-17
PT3625228T (pt) 2021-09-16
AR111808A1 (es) 2019-08-21
US20210113559A1 (en) 2021-04-22
LT3625228T (lt) 2021-10-25
PE20191811A1 (es) 2019-12-26
CO2019010505A2 (es) 2019-10-21
EA201992677A1 (ru) 2020-04-23
MX2019013638A (es) 2020-01-21
SI3625228T1 (sl) 2021-11-30
BR112019024105A2 (pt) 2020-06-02
MX388257B (es) 2025-03-19
IL270620A (en) 2022-12-01
KR20200007932A (ko) 2020-01-22
KR102626982B1 (ko) 2024-01-18
CR20190560A (es) 2020-02-10
UA125124C2 (uk) 2022-01-12
CL2019003274A1 (es) 2020-05-04
PL3625228T3 (pl) 2021-12-20
TW201900178A (zh) 2019-01-01
JP7159215B2 (ja) 2022-10-24
EP3625228A1 (en) 2020-03-25

Similar Documents

Publication Publication Date Title
AU2018268311B2 (en) Pyrimidine derivatives as PGE2 receptor modulators
KR102612649B1 (ko) Pge2 수용체 조절제로서의 벤조푸란 및 벤조티오페논 유도체
KR102352022B1 (ko) Pge2 수용체 조절제로서의 n-치환된 인돌 유도체
KR102612140B1 (ko) 피리미딘 유도체
AU2018269666B2 (en) Phenyl derivatives as PGE2 receptor modulators
HK40020597B (en) Pyrimidine derivatives as pge2 receptor modulators
HK40020597A (en) Pyrimidine derivatives as pge2 receptor modulators

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20230503

EEER Examination request

Effective date: 20230503